

Extraordinary General Meeting Q&A

With the continued risk posed by CV-19, the Company was conscious that some Shareholders may be unwilling or unable to attend the Meeting in person. Therefore, the Company invited Shareholders to submit questions in writing and undertook to provide answers to these where practical.

Only one question was received, and this was in respect of the disclosures in the Company's annual results published on 27 September 2021 relating to potential additional irregular expense claims and travel and other expense advances made to some Brazilian based members of staff (and which lacked appropriate and adequate supporting documentation or were not necessarily of a nature that appeared business related) over the period from January 2016 to March 2021. Whilst the value of the items identified was significant in aggregate, all these costs had been expensed through the Group's Income Statement in each of the relevant years and the value in each of the financial years concerned was below the levels of materiality for the preparation of the audited financial statements. As this matter is the subject of continuing legal proceedings in Brazil, the Company has been unable to interview the individuals who received these advances or expense reimbursements and has sought to avoid making unsubstantiated allegations which could be used against the Company. The unsubstantiated cash withdrawals, as reported in the announcement in August 2021, remained the principal focus of the Company's enquiries at that time to establish that there was no direct evidence of improper payments occurring within the scope of licencing and/or payments to obtain benefits in connection with public agencies (as confirmed in the Annual Results).